MaaT Pharma Provides an Update on the Application for Marketing Authorization of MaaT013 (Xervyteg®) in the treatment of acute Graft-versus-Host Disease

MaaT Pharma Provides an Update on the Application for Marketing Authorization of MaaT013 (Xervyteg®) in the treatment of acute Graft-versus-Host Disease

Raccontata damorningstar.com